XOMA (XOMA) Debuts IL-2 Monoclonal Antibody Program at SIC Annual Meeting
- Wall Street dips on Trump protectionism, Qualcomm drag
- Yahoo! (YHOO) Tops Q4 EPS by 4c; Sees Verizon Deal Closing in Q2, Not Q1
- Aetna's (AET) Humana (HUM) Takeover Blocked by Judge as Anticompetative
- Trump signs order withdrawing U.S. from Trans-Pacific trade deal
- After-Hours Stock Movers 1/23: (REXX) (MRCY) (SYNC) Higher; (FSM) (OCUL) (CASC) Lower (more...)
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
XOMA Corporation (Nasdaq: XOMA) unveiled its interleukin-2 (IL-2) monoclonal antibody program, a series of novel agents from its scientific discovery research unit, and announced the advancement of its parathyroid hormone receptor 1 (PTH1R) antibody antagonists program. These novel monoclonal antibodies are further examples of the capability of XOMA’s antibody platform and its expertise in the identification of novel oncology and oncology-related candidates with potential to positively affect outcomes in cancer patients.
“With our strategic focus on advancing our endocrine programs, we continue to seek ways to support and fund these efforts through discovery and licensing of our non-endocrine assets. For our oncology antibodies, we seek partners who have a deep commitment to and expertise in oncology drug development. An example of this is the TGF-beta antibody program that we licensed to Novartis last year, which we believe is advancing rapidly to initiation of clinical studies in the near future,” said John Varian, Chief Executive Officer of XOMA. “We have unique expertise in creating new antibodies to treat a variety of cancers and the side effects associated with currently marketed therapies. As with our TGF-beta antibody program, we plan to out-license our IL-2 and PTH1R antibody programs to organizations that can rapidly advance them into clinical development.”
IL-2 Monoclonal Antibodies ProgramImmune checkpoint inhibitors are transforming cancer treatment and revitalizing interest in immunotherapies. While efficacy has been observed in patients with advanced metastatic disease treated with checkpoint inhibitors, not all patients respond, and most responses are incomplete. Preclinical studies suggest that combining additional modalities with checkpoint inhibitors will provide opportunities to improve patient outcomes.
“IL-2 has long been recognized as an effective therapy for metastatic melanoma and renal cell carcinoma, but it has serious dose-limiting toxicities that prevent broad clinical use. We generated novel antibodies that, when given with IL-2, are intended to steer IL-2 to enhance its positive impact with less toxicity, potentially improving the therapeutic index over standard IL-2 therapy,” commented Paul Rubin, M.D., Senior Vice President, Research and Development, and Chief Medical Officer of XOMA.
A poster highlighting preclinical data from the IL-2 monoclonal antibodies program will be presented at The Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting & Associated Programs. The meeting will take place November 9-13 at the Gaylord National Hotel and Convention Center in National Harbor, Maryland.
Poster Presentation DetailsTitle: Novel IL-2/mAb complexes mediate potent anti-tumor immunity which is augmented with anti-PD-1 mAb therapyPoster Topic: Combinations: Immunotherapy/Immunotherapy Abstract Number: 454Poster Session Date: Saturday, November 12, 2016 Poster Session Time: 11:45 a.m. – 1:00 p.m. ET
The abstract can be viewed on the SITC website at www.sitcancer.org/2016.
PTH1R Monoclonal Antibodies ProgramXOMA has developed several unique functional antibody antagonists targeting PTH1R, a G-protein-coupled receptor involved in the regulation of calcium metabolism. These antibodies have shown promising efficacy in in vivo studies and could potentially address high unmet medical needs, including primary hyperparathyroidism (PHPT) and humoral hypercalcemia of malignancy (HHM). The Company plans to present preclinical data at a scientific conference later this year.
“Our PTH1R program began as an endocrine program, but its mechanism-of-action is potentially also beneficial to patients suffering from HHM. HHM is present in many advanced cancers and is caused by high serum calcium due to increased levels of the PTH1R ligand PTH-related peptide (PTHrP). Since current HHM treatments often fall short and many cancer patients die from ‘metabolic death’, XOMA’s PTH1R antibodies could be very beneficial for the treatment of HHM,” stated Patrick Scannon, M.D., Ph.D., Executive Vice President and Chief Scientific Officer of XOMA.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Eyegate Pharma (EYEG) Granted Canadian Patent for Proprietary Iontophoretic Formulation and Use
- Endo Int'l (ENDP) Agrees to Abandon Noncompetitive Pay-for-Delay in Settlement with FTC
- Avis Budget Group (CAR) Adopts Short-Term Stockholder Rights Plan
Create E-mail Alert Related CategoriesCorporate News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!